{
  "id": 5543684,
  "title": "Broker’s call: Emcure Pharma (Buy)",
  "url": "https://urgent.news/2026/09/04/brokers-call-emcure-pharma-buy",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-04T11:29:13.000Z",
  "source": {
    "name": "Hindu BusinessLine",
    "slug": "hindu-businessline",
    "url": "https://www.thehindubusinessline.com/markets/brokers-call-emcure-pharma-buy/article71427726.ece"
  },
  "original_language": "en",
  "account": "Pune-based Emcure Pharmaceuticals is a diversified pharmaceutical company that focuses on developing, manufacturing, and marketing a wide range of products in both domestic and international markets. The company's strong domestic presence includes a significant position in chronic and acute therapies, leadership in women's health, a substantial injectables franchise, and a unique front-end platform called Zuventus.\n\nEmcure has identified multiple low-risk growth opportunities through strategic in-licensing partnerships with global innovators. These partnerships allow the company to access established products and emerging therapy areas without significant R&D investments. The potential growth areas for Emcure include GLP-1, MASH, ophthalmics, dermatology, and consumer health, which provide additional optionality beyond its core portfolio.\n\nOn the international front, Emcure has established a robust front-end capability through a well-executed acquisition strategy in Canada and Europe. Simultaneously, the company maintains a vertically integrated supply chain in India. Emcure boasts a large and diverse product pipeline, strong positions in complex generics, and differentiated opportunities such as Semaglutide, Liposomal Amphotericin B, and Lenacapavir. These factors contribute to medium-term growth visibility for the company.\n\nConsidering Emcure's diversified domestic franchise, scalable international platforms, proven M&A execution, and multiple complex-product opportunities, the analyst values the company at ₹2,305 per share, based on a 30x FY28E EPS of ₹76.8.",
  "summary": "ICICI Direct",
  "key_points": [
    "Emcure Pharmaceuticals is a diversified pharmaceutical company.",
    "Company identifies low-risk growth opportunities through in-licensing.",
    "Analyst values Emcure at ₹2,305 per share based on FY28E EPS."
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}